Ovarian Cancer Research Alliance
Ovarian Cancer Research Alliance
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Ovarian Cancer Research Alliance? Learn more here.
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.
About this organization
Mission
The Ovarian Cancer Research Alliance (OCRA) is the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. As the voice for ovarian cancer, OCRA funds private research, advocates for increased federal research and awareness dollars and furthers policies that give women access to the services they need, as well as supports women and their families before, during and after a diagnosis. Collectively, the organization has invested over $110 million in private ovarian cancer research and has advocated to secure over $2.2 billion federal dollars dedicated to ovarian cancer research and awareness.
About
The Ovarian Cancer Research Alliance (OCRA) was created in January 2016, when the Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) combined forces into one full-spectrum organization for research, funding, advocacy, and patient support. Ovarian cancer is the deadliest of all gynecologic cancers and ranks fifth as the cause of cancer death in women. Each year there will be over 22,000 new cases of ovarian cancer in the United States, and approximately 15,500 women will die of the disease. The accomplishments of OCRA's programs reflect our commitment to the ovarian cancer community. Since 1998, OCRA has awarded 320 grants for ovarian cancer research to physicians and scientists at 71 leading medical centers, which is an investment totaling over $85 million. Thanks to the generosity of our donors, our investigators are working on many fronts to defeat ovarian cancer. By developing innovative strategies for early detection, and exploring the genetics that increase risk for ovarian cancer, we hope to save women's lives by finding the cancer early or stopping it before it even starts. Researchers are gaining insights into the many types of ovarian cancer and determining the origins of the disease, which may lead to more effective testing and treatment options. Furthermore, they are identifying new and better treatments to improve overall survival, prevent drug resistance, minimize side effects, and enhance patients' quality of life. Finally, they are deciphering how and why ovarian cancer spreads, and how to stop it. Accomplishments achieved as a result of OCRA grants include: shown that rucaparib extends progression free survival in ovarian cancer; helped explain resistance to chemotherapy; discovered that 18% of ovarian cancer cases involve inherited mutations; explored the role of estrogen in anti-tumor immunity; pinpointed two genes that trigger ovarian cancer; identified a new therapeutic strategy for clear cell ovarian cancer; shown how a PARP/immune therapy combo shows promise; demonstrated how gene therapy may help patients with recurrent disease; confirmed generic heart medication can prolong survival in ovarian cancer patients; shed light on how ovarian cancer grows; discovered that analyzing data from pap smears could help detect endometrial and ovarian cancer; established there is no link between obesity and risk for the most common type of ovarian cancer; shown that FGFR4 is a prognostic marker and therapeutic target for ovarian cancer; found that a subset of immune cells promote tumor growth; clarified which cell lines are the best fit for use in ovarian cancer research; defined similarities between some endometrial, breast and ovarian cancers; explained how an experimental drug may be helpful in fighting platinum-resistant ovarian cancer; identified areas of the human genome that are linked to increased risk for ovarian cancer; evaluated new experimental models to advance ovarian cancer research; and revealed how combining targeted agents is effective. In 2018, OCRA funded work that: helped focus on how ovarian cancer cells are disseminated throughout the body in an effort to determine the efficacy of an autoimmune drug thought to have potential for inhibiting ovarian cancer; explored an optical sensor implanted in mice that detected an ovarian cancer biomarker (HE4) which they hope to use for earlier detection; used proteomics, the large-scale study of proteins, to identify an important indicator for treatment and disease-free survival in patients with high grade serous ovarian cancer (the biomarker, known as CT45, is associated with better response to chemotherapy and longer disease-free survival); increased the amount of genetic counseling referrals to epithelial ovarian cancer patients by supplying patients with a genetics referral toolkit which the researchers believe vastly increased the amount of newly diagnosed patients who sought out genetic counseling and testing; and helped to explain why the body's natural immune response struggles to fight back against ovarian cancer by using ovarian tumors from humans and mice. Every dollar donated brings us closer to a cure for this devastating disease. For more information or to join us in our fight, please visit OCRA's website at www.ocrasite.org.
Interesting data from their 2019 990 filing
The filing clearly states the mission of the non-profit as “The mission of ovarian cancer research alliance (ocra) is to promote, advocate for and support scientific research as it relates to the causes, prevention, diagnosis, treatment, and cure for ovarian cancer; to provide education about ovarian cancer; to promote, advocate for and provide supportive services to persons affected by ovarian cancer; and to foster alliances to further those purposes.”.
When outlining its functions, they were explained as: “The mission of ovarian cancer research alliance (ocra) is to promote, advocate for and support scientific research as it relates to the causes, prevention, diagnosis, treatment, and cure for ovarian cancer; to provide education about ovarian cancer; to promote, advocate for and provide supportive services to persons affected by ovarian cancer; and to foster alliances to further those purposes.”.
- In compliance with legal regulations, the non-profit has reported their state of operation as NY.
- The filing records the non-profit's address for 2019 as 14 PENNSYLVANIA PLAZA NO 2110, NEW YORK, NY, 10122.
- As of 2019, the non-profit's form reports a total of 27 employees.
- Is not a private foundation.
- Expenses are greater than $1,000,000.
- Revenue is greater than $1,000,000.
- Revenue less expenses is -$1,332,609.
- The organization has 30 independent voting members.
- The organization was formed in 1994.
- The organization pays $2,358,419 in salary, compensation, and benefits to its employees.
- The organization pays $1,226,308 in fundraising expenses.